Poseida Joins Roche in $1.5B Deal to Deliver Next-Gen CAR-T Therapies
XTalks
NOVEMBER 29, 2024
129 Through this acquisition, Roche secures proprietary technologies such as Poseida’s Cas-CLOVER gene editing platform and in-house good manufacturing practice (GMP) manufacturing capabilities. Poseida’s genetic engineering platforms stand out for their precision, safety and potential to open new therapeutic avenues.
Let's personalize your content